Scopus
EXPORT Giannakouros T.

Leonidis G., Sigala I., Spathakis M., Kolios G., Giannakouros T., Nikolakaki E., Sarli V.
Synthesis of novel SRPK1-targeting hybrid compounds incorporating antimetabolites for cancer therapy
(2025) RSC Medicinal Chemistry, 16 (12), pp. 6285 - 6298, Cited 0 times.
DOI: 10.1039/d5md00731c

Koukiali A., Daniilidou M., Mylonis I., Giannakouros T., Nikolakaki E.
SR Protein Kinase 1 Inhibition by TAF15
(2023) Cells, 12 (1), art. no. 126, Cited 4 times.
DOI: 10.3390/cells12010126

Lesgidou N., Koukiali A., Nikolakaki E., Giannakouros T., Vlassi M.
PIM-1L Kinase Binds to and Inactivates SRPK1: A Biochemical and Molecular Dynamics Study
(2025) Proteins: Structure, Function and Bioinformatics, 93 (3), pp. 629 - 653, Cited 3 times.
DOI: 10.1002/prot.26757

Sigala I., Koukiali A., Miliotou A., Lougiaki P., Giannakouros T., Nikolakaki E.
An atm/chk2 signaling pathway induces nuclear translocation of srpk2 in cisplatin-treated hela cells
(2021) Processes, 9 (12), art. no. 2223, Cited 5 times.
DOI: 10.3390/pr9122223

Nikolakaki E., Sigala I., Giannakouros T.
Good Cop, Bad Cop: The Different Roles of SRPKs
(2022) Frontiers in Genetics, 13, art. no. 902718, Cited 19 times.
DOI: 10.3389/fgene.2022.902718

Sigala I., Koutroumani M., Koukiali A., Giannakouros T., Nikolakaki E.
Nuclear translocation of srpks is associated with 5-fu and cisplatin sensitivity in hela and t24 cells
(2021) Cells, 10 (4), art. no. 759, Cited 19 times.
DOI: 10.3390/cells10040759

Leonidis G., Koukiali A., Sigala I., Tsimaratou K., Beis D., Giannakouros T., Nikolakaki E., Sarli V.
Synthesis and Anti-Angiogenic Activity of Novel c(RGDyK) Peptide-Based JH-VII-139-1 Conjugates
(2023) Pharmaceutics, 15 (2), art. no. 381, Cited 3 times.
DOI: 10.3390/pharmaceutics15020381

Young A.N., Perlas E., Ruiz-Blanes N., Hierholzer A., Pomella N., Martin-Martin B., Liverziani A., Jachowicz J.W., Giannakouros T., Cerase A.
Deletion of LBR N-terminal domains recapitulates Pelger-Huet anomaly phenotypes in mouse without disrupting X chromosome inactivation
(2021) Communications Biology, 4 (1), art. no. 478, Cited 13 times.
DOI: 10.1038/s42003-021-01944-2

Charalambous V.Y., Sigala I., Ouzounthanasis K.A., Rizos S.R., Mantzourani C., Kokotou M.G., Fylaktakidou K.C., Giannakouros T., Nikolakaki E., Koumbis A.E.
SAR studies of chabrolonaphthoquinone B via rational design and synthesis of analogues - Cytotoxicity evaluation uncovers anticancer activity via mRNA splicing modulation
(2025) European Journal of Medicinal Chemistry, 300, art. no. 118175, Cited 0 times.
DOI: 10.1016/j.ejmech.2025.118175